试验数据显示，药物被测试，以减少心血管事件增加心脏病发作的风险 与（文档。文档元素]）{ 名=类名。取代（\/ \ BNO JS \ \/，“JS”）； } 如果（文件的URL。substring（7，9）= =“我”

那些与实验药物急性治疗急性冠脉综合征患者更可能经历更多的心血管事件–包括猝死、心脏病和中风的–比安慰剂组，根据克利夫兰诊所的临床研究中心协作研究（c5research）。

该vista-16结果（血管炎症抑制急性冠脉综合症的治疗16周）的试验，在去年为徒劳和可能造成的危害，提出了今天在美国心脏协会的科学会议2013日在达拉斯发表的同时美国医学协会杂志（JAMA）。

Varespladib inhibits production of the compound secretory phospholipase A2 (sPLA2), which promotes the vascular inflammation implicated in the development of atherosclerosis, or the clogging and hardening of arteries.VISTA-16 was designed to test whether the use of varespladib to reduce sPLA2 would lower the risk of cardiovascular events in patients with acute coronary syndrome。Patients with acute coronary syndrome have had a heart attack or experienced unstable angina, which can lead to a heart attack。

Rather than reduce additional cardiovascular events, including sudden death, heart attack, stroke, and unstable angina, the study found that patients treated with varespladib were more likely than those treated with placebo to experience these events。Both groups of patients were also treated with statin therapy and standard-of-care protocols。The primary endpoint, a composite of sudden death, heart attack, stroke and unstable angina, occurred in 6.1 percent of patients on varespladib compared to 5.1 percent of those on placebo。

此外，研究发现，急性有更大的心脏病风险相关，在急性和安慰剂组百分之2.2的研究人群中百分之3.4。

After reviewing this data, the trial’s independent Data and Safety Monitoring Board called off the trial in March 2012。

“Despite prior experimental and observational data suggesting that varespladib would have beneficial cardiovascular effects, this trial proves the contrary, that it is actually detrimental to cardiovascular morbidity and mortality,” said VISTA-16 executive committee chair Stephen J。Nicholls, MD, Ph D, senior consultant to Cleveland Clinic’s C5Research and Professor of Cardiology and Deputy Director at the South Australian Health & Medical Research Institute (SAHMRI) in Adelaide, Australia。

“The drug cannot be used to prevent cardiovascular events in patients with acute coronary syndrome,” he said。

The researchers do not know whether the outcome of the VISTA-16 trial is attributable to the varespladib molecule itself, or the across-the-board inhibition of sPLA2, which is known to have both protective and inflammatory affects on the cardiovascular system。

“We know that vascular inflammation plays a significant role in the development of coronary disease, and it’s important for the scientific community to continue to pursue drugs that may ease the inflammatory process and reduce cardiovascular risk,” said Steven Nissen, MD, senior author on the JAMA paper and Chairman of the Robert and Suzanne Tomsich Department of Cardiovascular Medicine at Cleveland Clinic。“Unfortunately, the complexity of the inflammatory process continues to confound our efforts at taming it.”

VISTA-16 was a double-blind, randomized, placebo-controlled trial designed to enroll more than 5,000 patients at 362 academic and community hospitals in Australia, Europe, India, New Zealand, and North America。It was an academically directed trial developed by an independent executive steering committee with input from the sponsor, Anthera Pharmaceuticals, and monitored by a Data and Safety Monitoring Board independent from both the executive committee and the sponsor。

（注：转载时请注明复诊网）